We discuss the rare case of a 68-year-old woman with VogtKoyanagi-Harada (VKH) 
Introduction
Prominent auditory and cutaneous pigmentary abnormalities coexist as clinical features in several diseases. Vogt-Koyanagi-Harada (VKH) syndrome is an autoimmune condition characterized by ocular, neurologic, auditory, and cutaneous manifestations. Otologic complaints may include sensorineural hearing loss (SNHL), tinnitus, and/or vertigo.
Th e primary treatment for symptoms associated with VKH syndrome is systemic corticosteroids. Although no study has specifi cally examined the eff ectiveness of systemic steroids on the otologic manifestations of VKH syndrome, a benefi t from their use has been suggested by the treatment of hearing loss associated with other autoimmune inner ear diseases. 1 Data on the potential utility of intratympanic steroids in autoimmune inner ear disease are limited to small case series, and no study has reported their use in VKH syndrome. 2 We describe the case of a patient with VKH syndrome who received two intratympanic steroid injections and experienced subsequent improvement of her ipsilateral auditory symptoms. We also review the various disorders associated with concomitant auditory and cutaneous pigmentary abnormalities.
Case report
A 68-year-old woman presented with a recurrence of a fl uctuating bilateral SNHL, a worsening of chronic tinnitus in her right ear, chronic fl uctuating vertigo, and vitiligo. In addition to her aural symptoms of approximately 15 years' duration, she also had a history of chronic uveitis, and she was taking medications for hypertension and diabetes.
Four months earlier, the patient had been diagnosed by the senior author (S.S.C.) with VKH syndrome, and she was prescribed an oral corticosteroid for her acute right-sided hearing deterioration. With treatment, she experienced improvement in her hearing and alleviation of her uveitis-related visual symptoms. However, she also developed refractory elevations in her blood pressure and blood glucose level. Th ese elevations could not be controlled through adjustments in her XprESS Indications For Use: To access and treat the frontal recesses, sphenoid sinus ostia, and maxillary sinus ostia/ethmoid infundibula in adults using a trans-nasal approach. The bony sinus outflow tracts are remodeled by balloon displacement of adjacent bone and paranasal sinus structures. From easy-to-use dilation and confirmation tools, to practice and patient resources, antihypertensive and diabetic medication regimens, which necessitated discontinuation of the oral steroids.
At the most recent presentation, the patient was noted to have patches of vitiligo on her face, arms, legs, and trunk. Findings on otolaryngologic and neurotologic examinations were normal bilaterally. Audiometric testing revealed a moderate to severe SNHL in the right ear and a moderate SNHL in the left ear at the speech frequencies (fi gure, A). Her speech discrimination scores were 80% for the right ear and 84% for the left .
Because the patient had previously experienced adverse reactions to systemic corticosteroid administration, the decision was made to proceed with an intratympanic dexamethasone injection. A total of 0.5 ml of dexamethasone in a 10-mg/ml concentration was injected into the right middle ear for chemical labyrinthotomy via round-window membrane perfusion. Th e patient experienced transient dizziness but no other temporary or long-term complications.
Repeat audiometry 4 weeks following the injection showed a 10-dB improvement at 1,000 Hz. At that point, a second intratympanic injection was administered, and an audiometric examination performed 2 weeks later revealed an additional 5-to 10-dB improvement across multiple frequencies from 250 to 2,000 Hz (fi gure, B). Although the patient's speech discrimination scores did not substantially change (84% for the right ear and 88% for the left ), she did report a subjective alleviation of the tinnitus in her right ear.
During 18 months of clinical follow-up, serial audiometry demonstrated an improvement (20 to 30 dB) to near normal in her right-sided hearing thresholds at the speech frequencies; however, the moderate SNHL persisted in her left ear. Her condition did not necessitate any additional intratympanic injections.
Discussion
Several disorders marked by prominent cutaneous pigmentary abnormalities are associated with hearing dysfunction. Th e pathophysiologic basis of this association is related to disease processes that aff ect melanocytes, 
Figure. Audiometric air-conduction thresholds are seen before intratympanic steroid therapy (A) and aft er the second intratympanic steroid injection in the right ear (B) (× = left ear; • = right ear)
which are neural-crest-derived cells found in the skin, eye, ear, and meninges. Within the skin, melanocytes are found in the basal epidermal layer; in the cochlea, they are located in the stria vascularis. Th e function of melanocytes in the cochlea remains unclear. Animal models have suggested that increased pigmentation in the stria vascularis may exert a protective eff ect against noise-induced hearing loss. 3 Moreover, a protective role for melanin is implied by the observation that individuals with darker skin pigmentation are less susceptible to noise-induced hearing loss, presumably because of a higher density of melanin in the cochlea. 3 Th e most common of hereditary disorders aff ecting melanocytes is Waardenburg syndrome, which is an autosomal dominant condition marked by SNHL, skin and hair hypopigmentation (piebaldism), and heterochromia iridis. Th ese integumentary and auditory manifestations are believed to occur as the result of a failure of proper melanocyte diff erentiation during embryogenesis. 4 Albinism is another hereditary disease with multiple genetic etiologies that all result in a common pathophysiologic process of melanocyte dysfunction and impaired or absent melanin production. Rare subtypes of ocular albinism have been associated with SNHL; deafness at birth is seen in the autosomal form, and late-onset hearing loss is seen in an X-linked variant. 4 Vitiligo is an acquired disorder characterized by a loss of functional melanocytes, presumably via autoimmune destruction. While most patients with vitiligo do not report subjective auditory impairments, abnormal VKH syndrome is another disease that occurs as a result of an autoimmune destruction of melanocytes. It is most prevalent in nonwhite patients between the ages of 20 and 50 years. 6 Patients with VKH syndrome typically present with symptoms of aseptic meningitis initially followed by bilateral uveitis later. Dermatologic changes occur several weeks or months aft er the onset of the ocular symptoms, and they may include poliosis, vitiligo, and alopecia. Auditory symptoms associated with VKH syndrome occur with variable frequency; patients may experience hearing loss, tinnitus, and/or vertigo that typically coincides with the onset of ocular pathology.
Th e mainstay of evaluation for the auditory symptoms of VKH syndrome is audiometry, although the nature and extent of hearing loss associated with VKH syndrome has not been well described. A recent study of patients with VKH syndrome reported by Ondrey et al revealed that 5 of 24 patients had SNHL worse than what was seen in age-matched control populations reported in the previously published literature. 6 However, these 5 hearing losses exhibited no clear pattern with respect to threshold or frequency.
Th e most commonly used treatment for the ocular manifestations of VKH syndrome is systemic corticosteroids. Patients with SNHL associated with VKH syndrome are also typically treated with oral steroids. While no study has specifi cally evaluated the eff ectiveness of oral steroids in VKH syndrome, other patients with autoimmune inner ear disease have experienced modest but signifi cant improvements in hearing aft er treatment with oral prednisone over a 4-week period. 1 Most clinical evidence supporting the use of intratympanic steroids is derived from patients with sudden SNHL or Ménière disease. 2, 7, 8 Several studies have also indicated a benefi t from steroids in smaller numbers of patients with autoimmune inner ear disease, although no previous study has described their use specifi cally for treatment of VKH-syndrome-related SNHL. 2 Accepted indications for intratympanic steroids are as a second-line treatment when oral steroids fail to improve hearing and when systemic steroids are contraindicated. Systemic side eff ects secondary to plasma absorption of intratympanic steroids are theoretically possible but unlikely. No signifi cant plasma absorption has been found in animal models, 9 and in human studies, the administration of intratympanic steroids has not increased blood glucose levels in diabetic populations. 10 In view of the retrospective nature of the available data in the literature, no consensus has been reached on the most eff ective type and dose of intratympanic steroids, the number of injections, and the specifi c delivery technique.
In our patient, the untreated left ear served as a control for our intervention. While the hearing thresholds in her right ear improved over time following intratympanic steroid administration, thresholds remained largely unchanged in the left ear. Th is fi nding suggests that the observed improvement in our patient's right-sided hearing were not simply a refl ection of the characteristic waxing and waning nature of disease severity that is associated with VKH syndrome and other autoimmune inner ear processes. Rather, it suggests that intratympanic steroid administration might have induced lasting qualitative changes in the autoimmune process aff ecting the patient's inner ear.
